Beam Therapeutics: Base Editing Offers Billion-Dollar Potential in Genetic Precision Medicine
Reading Time: 3 minutes
Beam Therapeutics will submit the FDA approval application for BEAM-101 for the treatment of severe sickle cell disease by 2026. BEAM-302 for Alpha-1-Antitrypsin Deficiency (AATD) is approaching accelerated FDA approval, and IND approval from the FDA for clinical trials with BEAM-304 for the treatment of phenylketonuria (PKU). Revenue growth could significantly accelerate starting in 2028. With a cash reserve of $1.2 billion, funding is secured until 2029. Beam Therapeutics (BEAM) has specialized as a biotech company in the clinical...
Read this article now with a free account.
Your benefits:
- Every month, you can read 5 articles from the premium section for free.
- Monthly 2 trial issues of the Trader newspaper for free.
- Create a personal watchlist with an overview of news about your stock.
